Expert-Led Webinars

Webinar title:

In Vivo Pharmacology for T Cell Engagers: A Comprehensive Multi-Species Translational Platform

Abstract:

In vivo studies often present challenges in evaluating T cell engagers (TCEs) due to their complex MOA and pharmacology. Reliable interpretation of PK/PD, efficacy, and safety data requires rational study design and fit-for-purpose models to improve translational relevance.

This webinar will introduce multiple in vivo models across species (cynomolgus NHPs, hFcRn mice, human PBMC/CDX models) for translational evaluation of TCE exposure-response relationships. Through detailed case studies, you will gain practical insights into TMDD-driven nonlinear clearance and associated PK/PD responses in NHP studies, dose-dependent toxicity, and correlating tissue T cell infiltration and translational PK studies, helping to refine study design, mitigate preclinical risks, and streamline the path toward clinical success.

In this webinar, you will discover:

• Rational study design to align preclinical models with PBMC/CDX models for TCEs
• Key considerations for selecting optimal species and models to maximize translational relevance
• Interpretation of unique TCE exposure-response patterns and histological datasets to support go/no-go decisions
• Proactive troubleshooting to overcome preclinical challenges and maintain accelerated timelines

Speaker:

Zhili Yao, Ph.D., Director, CRO Services

Register Now

Webinar title:

In Vitro Assays for ADC Discovery: From Assay Design to Translational Insights

Abstract:

Antibody-drug conjugates (ADCs) represent a powerful therapeutic modality for solid tumors and hematological malignancies. However, their development is often challenged by limited translational insights, narrow therapeutic windows, and the difficulty in differentiating new candidates from existing therapies.

This webinar will showcase how practical in vitro assay design can address key challenges for ADCs in oncology. We will introduce a set of bioassays, including cytotoxicity, bystander killing, internalization, and serum stability, to evaluate drug MOA, specificity, and potency. Real-world case studies will highlight how these data-driven approaches support candidate selection, enable clear differentiation of new candidates, and improve prediction of in vivo performance.

In this webinar, you will learn how to:

• Design in vitro models and select appropriate cell lines to differentiate new ADC candidates
• Apply core assays to define and optimize the therapeutic window
• Leverage advanced analytical tools (high-content imaging, flow cytometry, IncuCyte, etc.) to generate robust, quantitative data
• Turn assay results into practical insights to bridge discovery and translational studies

Speaker:

Zhuo Mao, Ph.D., Director, CRO Services

View Recording

Webinar title:

Mass Spec Enables More Definitive Biologics Drug Discovery and Optimization

Abstract:

The complexity and heterogeneity of protein therapeutics present significant challenges in biologics discovery, as post-translational modifications (PTMs) and sequence variants can affect product quality, safety, and efficacy. Mass Spec (MS) has emerged as a powerful tool for structure and function analysis with unmatched precision and high-throughput (HTP) capabilities.

This webinar will showcase advanced MS methodologies, such as HTP Intact Mass, peptide mapping, and glycan analysis, for both qualitative physicochemical characterization and quantitative analysis for target validation and PK assessment. Real-world case studies will demonstrate how these approaches deliver comprehensive structure and function insights, driving more definitive biologics discovery and optimization.

You’ll discover how MS can:

• Provide in-depth protein characterization to guide discovery, engineering, and optimization
• Support robust in vitro and in vivo PK analysis to mitigate development risks
• Address early-stage developability challenges with tailored workflows

Speaker:

Lei Guo, Ph.D., Senior Director, CRO Services

View Recording

Webinar title:

Building Next-Gen TCR-TCEs: High-Titer CHO Expression & Optimized TCR Affinity Maturation

Abstract:

As the demand for novel biologic drug modalities continues to rise, TCR-TCE is emerging as a promising modality. However, key challenges remain, particularly the production of soluble TCR (sTCR) and low affinity of TCRs derived from phage libraries.

Join our webinar to explore two innovative platforms designed to overcome these challenges: our groundbreaking WuXian Transient™ expression system for high-titer, high-throughput sTCR expression, and optimized TCR affinity maturation processes that achieve ~10,000-fold K_D improvement. Through real-world case studies, we will demonstrate how these platforms can be seamlessly integrated to generate affinity-maturated, high-titer TCR candidates, serving as essential building blocks for next-gen TCR-TCE therapeutics.

In this webinar, you will discover:

• High-titer CHO production of sTCRs (~100 mg/L) and TCR-TCE using WuXian Transient™ expression system.
• Optimized TCR affinity maturation from phage, routinely improving K_D by ~10,000-fold (from 10-100 μM).
• Integration of high-throughput CHO expression and TCR affinity maturation processes to efficiently generate building blocks for TCR-TCEs.

Speaker:

Jiansheng Wu, Ph.D., Senior VP, Head of CRO Services

View Recording

Webinar title:

In Vitro Assays for T Cell Engagers – From Bench to Data-Driven Decisions

Abstract:

Standard bioassays often fall short when evaluating T cell engagers due to their diverse mechanisms of actions (MOAs) and functional complexity. To generate meaningful preclinical data, context-specific in vitro models are essential.

In this webinar, we will explore the strategic application of tailored bioassays for T cell engagers (TCEs) in oncology. Through real-world case studies, we will demonstrate how rational assay design, such as T cell activation, redirected killing, cytokine release, and target-specific inhibition, can support robust assessment of drug potency, specificity, and MOAs.

In this webinar, you will learn:

• Proven strategies for assay design, optimization, and biological interpretation in preclinical development
• How in vitro models like bispecific format evaluation can bridge discovery and translational relevance
• Practical approaches for transforming complex bioassay data into actionable insights to guide drug development

Speaker:

Rachel Wang, Ph.D., Associate Director (SME), CRO Services

View Recording

Webinar title:

Bispecific Antibody Discovery: Practical Strategies from MOA to Preclinical Candidates

Abstract:

Bispecific antibodies (BsAbs) enable diverse therapeutic MOAs such as retargeting cytotoxic effector cells, modulating receptor activity, and selectively recognizing pathogenic cells. However, advancing bsAbs from concept to preclinical candidates remains challenging, requiring comprehensive insights and technical expertise at every stage. 

This webinar will explore practical strategies for bsAb discovery, from lead identification and high-throughput (HTP) production to in vitro assays and in vivo studies. Through real-world case studies, we will highlight one-stop, modular solutions for bsAb design, screening, and functional characterization to support the development of next-generation bsAb therapeutics. 

In this webinar, you will learn:

• Advanced antibody discovery platforms for biology-driven lead identification 
• Innovative Quick ‘n’ Clean platform for HTP bsAb production, unlocking optimal pairings rapidly 
• Comprehensive in vitro functional assays across T-cell engagers (TCEs), immune checkpoint inhibitors, and autoimmune diseases 
• Extensive in vivo efficacy models and well-established PK/PD/Tox platforms delivering time- and cost-effective solutions

Speaker:

Macy Jin, MD, Director, CRO Services

View Recording

Webinar title:

In Vivo Pharmacology Maximizing Translational Relevance via NHP/Murine Models

Abstract:

In vivo pharmacology remains the gold standard for evaluating the efficacy and pharmacodynamics of therapeutic candidates in preclinical development. Selecting precise, clinically relevant animal models is critical for generating high-quality data and ensuring a seamless transition to clinical trials. This webinar will showcase our end-to-end, multi-species in vivo platform, leveraging NHP and murine models to support a comprehensive suite of PK/PD/Tox, efficacy, and histology assessments. Whether you’re developing mAbs, bsAbs, ADCs, or novel modalities, this session will equip you with practical insights to refine study design, mitigate risks, and streamline the path to clinical success.

In this webinar, you will learn:

• Rational study design to align preclinical models with human disease biology
• Key considerations for selecting optimal species and models that maximize translational relevance of PK/PD and efficacy
• Data interpretation to extract actionable insights from complex pharmacodynamic and histological datasets
• Proactive troubleshooting to overcome preclinical challenges and accelerate timelines

Speaker:

Zhili Yao, Ph.D., Director, CRO Services

View Recording

Webinar title:

Early-Stage Developability Assessment for Lead Optimization

Abstract:

Early-stage biologics discovery often prioritizes binding affinity but overlooks critical developability factors, leading to CMC and clinical challenges. This webinar introduces the Micro Developability platform, a high-throughput analytical suite that requires <1 mg of antibody per assay to assess key developability attributes like sequence liability, PK and stability. Through case studies, we will illustrate how these early assessments optimize leads, mitigate downstream risks, and facilitate a smooth transition to CMC.

You will gain valuable insight into:

• High-throughput assays with robust performance and high sensitivity for biophysical and PK profiling, including AC-SINS, BVP/DNA/insulin ELISA, FcRn affinity and serum stability
• Integrated developability assessments combining in silico modeling and in vitro assays to identify potential risks in early stage
• Micro-developability strategy for new modalities

Speaker:

Lei Guo, Ph.D., Director, CRO Services

View Recording

Webinar title:

Achieving High Titer & Superior Purity Across Diverse Bispecific Antibody Formats

Abstract:

Bispecific antibodies (BsAbs) are at the forefront of therapeutic innovation, but their production is often hindered by challenges such as low titers and difficult-to-remove impurities like homodimers and mispaired species. Additionally, each BsAb format presents unique complexities in the production process.

This webinar will showcase innovative solutions to these challenges, including ultra-high-titer CHO expression systems, optimized chain ratios, and Intact Mass-assisted purification processes tailored for various formats like CrossMab, WuXiBody, and others. Through detailed case studies, we will demonstrate how these approaches consistently achieve over 98% heterodimer purity and endotoxin levels below 0.1 EU/mg.

In this webinar, you will learn:

• Innovative strategies to overcome low titers, mispaired species and homodimers.
• Advanced chain ratio optimization for formats like CrossMab and WuXiBody, improving expression and titer.
• Case studies illustrating Intact Mass-assisted purification tailored for various formats, such as CrossMab, WuXiBody, and ScFv-Fab, consistently achieving heterodimer purity >98% and endotoxin levels <0.1 EU/mg.

Speaker:

Jiansheng Wu, Ph.D., Vice President, Head of CRO Services

View Recording

Webinar title:

Innovative Production and Engineering Strategies for Fab, ScFv & VHH

Abstract:

Antibody fragments like Fab, ScFv, and VHH are emerging stars in antibody drug development, utilized both as standalone molecules and as building blocks of bispecific antibodies. However, their production and engineering face numerous challenges, including issues related to yield, purity, throughput, and stability. In this webinar, we will unveil innovative strategies to overcome these challenges, tailored to the distinctive characteristics of Fab, ScFv, and VHH. We’ll provide key insights into molecular design, high-titer CHO transient and stable pool production, and effective purification methods to accelerate your development of antibody fragments.

In this webinar, you will learn:

• Novel strategies to tackle common production challenges like low yields, throughput issues, and impurities in antibody fragment production.
• Advanced molecule engineering and linker design to mitigate aggregation and increase yield.
• Tailored approaches for optimizing the production of Fab, ScFv, and VHH, with a focus on specific strategies for each fragment type.

Speakers:

Jiansheng Wu, Ph.D., Vice President, Protein Sciences

View Recording

Webinar title:

Groundbreaking Innovations: High-Titer CHO Expression of Miniproteins & T-Cell-Related Proteins

Abstract:

As the demand for novel biologic drug modalities continues to rise, miniproteins and T-cell-related proteins are emerging as promising candidates. However, the production of these proteins for biologics development has posed numerous challenges. Join our upcoming webinar to explore two groundbreaking platforms that overcome common challenges and are revolutionizing the production of miniproteins and T-cell-related proteins, significantly accelerating biologics development.

In this webinar, you will learn:

• How the Miniprotein Line surpasses traditional E. coli methods, utilizing high-titer CHO system to enhance expression and achieve extra-low endotoxin levels.
• How the T-Cell Mate platform efficiently produces challenging T-cell-related proteins, including sTCR, TCR-Ab fusions and SCT, enabling high throughput and yields critical for advancing therapeutic proteins.
• Case studies demonstrating the successful use of these innovative platforms in producing high-purity miniproteins and T-cell-related proteins.

Speakers:

Jiansheng Wu, Ph.D., Vice President, Protein Sciences

View Recording